Delgocitinib for treating moderate to severe chronic hand eczema [ID6408]

Suggested remit: To appraise the clinical and cost effectiveness of delgocitinib within its marketing authorisation for treating moderate to severe chronic hand eczema.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6408

Provisional Schedule

Expected publication:

01 October 2025

Project Team

Project lead

Thomas Feist

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors

Leo Pharma

Others

Department of Health and Social Care

 

Health Technology Wales (HTW)

 

NHS England

Patient carer groups

National Eczema Society

Professional groups

British Association of Dermatologists

 

Royal College of Physicians

Comparator companies

AAH Pharmaceuticals (alitretinoin, tacrolimus) (confidentiality agreement not signed, not participating), Accord UK (tacrolimus) (confidentiality agreement not signed, not participating), Advanz Pharma (methotrexate) (confidentiality agreement not signed, not participating), Aspen (azathioprine, mycophenolate mofetil) (confidentiality agreement not signed, not participating), Cipla UK (methotrexate) (confidentiality agreement not signed, not participating)

 

Dexcel Pharma (ciclosporin) (confidentiality agreement not signed, not participating), Ennogen Healthcare (alitretinoin) (confidentiality agreement not signed, not participating), Hospira (methotrexate) (confidentiality agreement not signed, not participating), Leo Pharma (tacrolimus) (confidentiality agreement not signed, not participating), Medac (methotrexate) (confidentiality agreement not signed, not participating), Medihealth (tacrolimus) (confidentiality agreement not signed, not participating), Morningside Healthcare (methotrexate) (confidentiality agreement not signed, not participating), Mylan (azathioprine; ciclosporin, (confidentiality agreement not signed, not participating)mycophenolate mofetil), Nordic Pharma (methotrexate) (confidentiality agreement not signed, not participating)

 

Nova (azathioprine; mycophenolate mofetil) (confidentiality agreement not signed, not participating), Novartis (ciclosporin) (confidentiality agreement not signed, not participating), Orion Pharma (methotrexate) (confidentiality agreement not signed, not participating), Rosemont Pharmaceuticals (methotrexate) (confidentiality agreement not signed, not participating)

 

Sandoz (methotrexate,) (confidentiality agreement not signed, not participating), Santen UK (ciclosporin) (confidentiality agreement not signed, not participating), Strides Pharma (azathioprine, mycophenolate mofetil) (confidentiality agreement not signed, not participating)

 

Teva UK (tacrolimus) (confidentiality agreement not signed, not participating)

 

Tillomed Laboratories (azathioprine, mycophenolate mofetil) (confidentiality agreement not signed, not participating), Viatris (pimecrolimus) (confidentiality agreement not signed, not participating)

 

Stiefel Laboratories (alitretinoin) (confidentiality agreement signed, participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual